BenevolentAI Unveils Groundbreaking Drug Discovery Platform Targeting Ulcerative Colitis
BenevolentAI’s Drug Discovery Platform Identifies Novel Target for Ulcerative Colitis
London-based AI innovator BenevolentAI has successfully identified a new biological target for treating ulcerative colitis using its advanced drug discovery platform. This significant discovery was achieved through the use of the company’s target identification tools and machine learning models, which allowed scientists to identify and experimentally validate the candidate without any prior references in published literature or patents linking the specific gene to the disease.
Anne Phelan, Chief Scientific Officer at BenevolentAI, stated, “Ulcerative colitis is a chronic disease that affects 0.2% of the US population and impacts 1.6 million patients across major markets. Unfortunately, it is inadequately managed with current treatment options. Our innovative preclinical candidate aims to fulfill the pressing need for a safe and effective oral therapy. It has shown an improved safety and tolerability profile in comparison to existing IBD treatments. We’re utilizing patient-derived molecular descriptors to accurately target patient subgroups, enhancing trial designs and their potential for success.”
After the identification phase, BenevolentAI harnessed its molecular design capabilities to create a potential oral drug that is peripherally restricted. This candidate has been experimentally validated using ex-vivo colon samples from ulcerative colitis patients who did not respond to existing therapies. Joanna Shields, Chief Executive Officer of BenevolentAI, remarked, “The nomination of a drug candidate linked to a novel target for ulcerative colitis identified through our AI-driven drug discovery platform marks a pivotal moment for BenevolentAI and offers a promising new treatment option for this challenging condition.” BenevolentAI plans to advance this asset into clinical trials in early 2023.
For additional insights, consider attending Digital Transformation Week North America, set for November 9-10, 2021, a virtual event focused on advanced digital transformation strategies.
AI and Machine Learning: Exploring Applications and Impacts
Artificial Intelligence (AI) and machine learning are rapidly transforming industries by enhancing decision-making processes and automating various workflows. With advancements in these technologies, organizations are increasingly leveraging their capabilities to improve efficiency and productivity.
Applications Across Sectors
From healthcare to finance, AI applications are becoming more prevalent. In healthcare, for instance, machine learning algorithms aid in diagnosing diseases by analyzing medical imaging data. The finance sector utilizes AI for fraud detection and risk assessment, allowing institutions to enhance security and protect consumer assets.
Ethical Considerations
As AI technology advances, ethical concerns arise regarding privacy, bias, and accountability. Companies are challenged to create transparent systems that ensure fair treatment of users and mitigate risks associated with biased data. Responsible AI development calls for implementing frameworks that promote ethical standards throughout the lifecycle of AI projects.
Future of AI and Machine Learning
The future of AI and machine learning holds promising potential. As capabilities continue to expand, sectors ranging from robotics to surveillance will see incredible transformations. Continuous research and innovation will ensure AI remains adaptable and capable of addressing emerging challenges in technology and society.
About Us
We are committed to delivering the latest news and insights on artificial intelligence and technology trends. Stay informed about developments that impact industries by subscribing to our updates for premium content straight to your inbox.